{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Coral+Gables&page=4&state=Florida", "query": { "state": "Florida", "city": "Coral Gables", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 173, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Coral+Gables&page=5&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Coral+Gables&page=3&state=Florida&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T07:38:38.603Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05633602", "title": "Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 838, "start_date": "2023-03-14", "completion_date": "2028-03-15", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 566, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05633602" }, { "nct_id": "NCT05773274", "title": "Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Digestive System Neuroendocrine Tumor G1", "Metastatic Digestive System Neuroendocrine Tumor G2", "Unresectable Digestive System Neuroendocrine Tumor G1", "Unresectable Digestive System Neuroendocrine Tumor G2" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-01-12", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05773274" }, { "nct_id": "NCT05879926", "title": "Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ovarian Function Suppression + Aromatase Inhibitor", "type": "DRUG" }, { "name": "Adjuvant Chemotherapy + Ovarian Function Suppression", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "FEMALE", "summary": "18 Years to 60 Years · Female only" }, "enrollment_count": 3960, "start_date": "2023-10-18", "completion_date": "2034-07", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 1226, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05879926" }, { "nct_id": "NCT01013649", "title": "Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Pancreatic Intraductal Papillary-Mucinous Neoplasm", "Stage I Pancreatic Cancer AJCC v6 and v7", "Stage II Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 546, "start_date": "2010-04-05", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 678, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Auburn, California + 438 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01013649" }, { "nct_id": "NCT03952585", "title": "De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Basaloid Squamous Cell Carcinoma", "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Oropharyngeal Squamous Cell Carcinoma", "Papillary Squamous Cell Carcinoma", "Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Image Guided Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 384, "start_date": "2019-10-09", "completion_date": "2026-12-11", "has_results": true, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 493, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03952585" }, { "nct_id": "NCT06500455", "title": "Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Metastatic Digestive System Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fractionated Stereotactic Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 274, "start_date": "2024-12-12", "completion_date": "2033-06-30", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 262, "location_summary": "Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06500455" }, { "nct_id": "NCT04340141", "title": "Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Adenosquamous Carcinoma", "Resectable Pancreatic Adenocarcinoma", "Stage I Pancreatic Cancer AJCC v8", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Resection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2020-10-13", "completion_date": "2030-11-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 441, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 325 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04340141" }, { "nct_id": "NCT05312879", "title": "Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Proteinuric Kidney Disease" ], "interventions": [ { "name": "VX-147", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "10 Years to 65 Years" }, "enrollment_count": 522, "start_date": "2022-03-30", "completion_date": "2030-05-07", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 223, "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 144 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05312879" }, { "nct_id": "NCT03831932", "title": "Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Elastography", "type": "PROCEDURE" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Telaglenastat Hydrochloride", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-03-16", "completion_date": "2027-03-13", "has_results": true, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Coral Gables, Florida • Deerfield Beach, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03831932" }, { "nct_id": "NCT02635009", "title": "Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Extensive Stage Small Cell Lung Carcinoma", "Limited Stage Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Three-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 418, "start_date": "2015-12-22", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-10-24T07:38:38.603Z", "location_count": 270, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 217 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635009" } ] }